INTRODUCTION {#s1}
============

The biologically active form of vitamin D is 1α,25-dihydroxyvitamin D~3~ \[1α,25(OH)~2~D~3~\], and it plays a key role in calcium and phosphorus metabolism. More recently, important pleiotropic effects have been described including: cell proliferation inhibition, differentiation, anticarcinogenic effects, innate-stimulation and adaptive immunity inhibition, inflammation inhibition as well as several other endocrine and developmental effects ([@BIO033670C22]; [@BIO033670C35]; [@BIO033670C4]; [@BIO033670C23]). This form binds to the vitamin D receptor (VDR) and regulates gene expression in a ligand-dependent manner ([@BIO033670C21]; [@BIO033670C23]). VDR is expressed in skeletal muscle tissue at different stages, from myoblasts (mononucleated cells) to myotubes (multinucleated cells). Furthermore, the evidence of VDR presence has been reported in rodent skeletal muscle cell lines ([@BIO033670C39]), in chicken myoblasts monolayers ([@BIO033670C5]) and in human skeletal muscle cells ([@BIO033670C11]).

The traditional activity of 1α,25(OH)~2~D~3~ to modulate gene transcription is also complemented with its ability to regulate intracellular, extranuclear pathways and cytoplasmic signaling cascades. These cytoplasmic actions are generally regarded to be rapid responses, taking place from within seconds to minutes. Numerous studies detail the ability of 1α,25(OH)~2~D~3~ to affect intracellular calcium levels as well as intracellular signaling pathways involving kinases and phosphatases. The activation of different signaling pathways is dependent on the cell type, thus providing an avenue to explain the pleiotropic effects of vitamin D ([@BIO033670C43]; [@BIO033670C2]; [@BIO033670C38]; [@BIO033670C23]). Low vitamin D levels are associated with different degrees of muscle dysfunction; consequently, supplementation with vitamin D has generally shown beneficial effects. Among dietary supplements the use of vitamin D~3~ has been shown to improve bone health and muscle strength of broilers ([@BIO033670C34]; [@BIO033670C29]; [@BIO033670C17]), feedlot steers' health ([@BIO033670C33]) and meat tenderness ([@BIO033670C32]). However, 1α,25(OH)~2~D~3~ is not available for animal nutrition because of high costs, but it has been found that a few plants species have 1α,25(OH)~2~D~3~ and other vitamin D~3~ metabolites ([@BIO033670C30]). *Solanum glaucophyllum* plants accumulate 1α,25(OH)~2~D~3~-glycosides, and so their leaves become a natural source of the active form of vitamin D. *S.* *glaucophyllum* leaf extract (SGE) is used in a cold water solution for poultry breeding ([@BIO033670C3]). One advantage of SGE is that 1α,25(OH)~2~D~3~ can become available quickly when entering the body as there is no need for the two metabolic steps to become active ([@BIO033670C36]). The active component present in the plant extract has been shown to induce calcium and phosphorus transport and thus it is recommended for treatment of liver and/or kidney function impairment in older animals and stress conditions ([@BIO033670C3]; [@BIO033670C13], [@BIO033670C14]).

We have previously demonstrated that SGE increases VDR, myogenin, and myosin heavy chain protein levels during the first 48 h of C2C12 muscle cell line differentiation ([@BIO033670C19]). Moreover, SGE improves the growth and differentiation of C2C12 cells at the onset of myogenesis, increasing cellular mass and myotube fusion ([@BIO033670C19]). In this work, we further studied the effects of SGE on the signaling pathways involved in C2C12 muscle cell differentiation.

RESULTS AND DISCUSSION {#s2}
======================

Skeletal muscle differentiation involves a complex process where a broad number of signal pathways are coordinated. At the beginning of the differentiation, satellite cells (muscle stem cells) commit to myogenic precursor cells known as myoblasts. Successively, a series of regulatory factors collaborate to differentiate the myoblasts. To complete this process, mononuclear cells or myocytes align and fuse to form multinuclear cells or myotubes ([@BIO033670C18]; [@BIO033670C31]). To further investigate the mechanism of SGE on the differentiation of muscle cells, the murine skeletal muscle cell line C2C12 was chosen. The regulation of the cell cycle in C2C12 muscle cells treated with fetal bovine serum (FBS) or synthetic 1α,25(OH)~2~D~3~ has been previously reported ([@BIO033670C25]). In the present study, we first examined the effect of SGE on C2C12 cell cycle progression. To that end, cells were deprived of FBS for 16 h to synchronize the cultures at a time in which 85% of the cells were growth-arrested in the G0/G1-phase, as it was previously described ([@BIO033670C25]). Then, arrested cells were stimulated with 10 nM of SGE for different periods of time (6--48 h) and analyzed by flow cytometry. [Fig. 1](#BIO033670F1){ref-type="fig"}A shows that the percentage of cells in the G0/G1-phase increased after 6 h of SGE treatment whereas the G2/M phase declined. Progression of the cell cycle from G1 to S-phase continued and an S-phase peak was observed at 12 h. After completion of the S-phase, an increase in the G0/G1-phase was observed at 24 h, showing that one round of the cell cycle had been completed and cells had begun preparing to start posterior differentiation. This cell cycle pattern prompted by SGE was similar to the one reported in C2C12 stimulated with synthetic 1α,25(OH)~2~D~3~ ([@BIO033670C25]). Fig. 1.**Cell cycle progression of C2C12 skeletal muscle cells after SGE treatment: role of p38 MAPK.** A. This panel shows a representative histogram and DNA quantification from three independent experiments showing the percentage of cells in G0/G1-, S- and G2/M-phases (Y-axis label) ±s.d. Data were analyzed by one way ANOVA, followed by *t*-test, \*\**P*\<0.01. B. This panel presents a representative histogram and DNA quantification from four independent experiments expressing the percentage of cells in G0/G1-, S- and G2/M-phases (Y-axis label) ±s.d. in combined bars graphs. Different letters mean statistical differences with Tukey test.

Several downstream signaling pathways, including p38 MAPK, Rho family small GTPases and AKT, are implicated in cell myogenesis ([@BIO033670C20]; [@BIO033670C40]; [@BIO033670C8]). Transient or sustained MAPKs activation regulates cellular fate mechanisms such as proliferation and differentiation. The best characterized mammalian MAPKs are grouped into four main modules, the ERK1/ERK2, JNK, p38 and ERK5 modules, but more subgroups might exist ([@BIO033670C27]). When activated, MAPKs translocate into the nucleus and induce transcription factor phosphorylation either directly or indirectly through downstream kinases ([@BIO033670C27]). p38 MAPK has been identified as an important signaling pathway to promote skeletal muscle differentiation. Furthermore, p38 MAPK inhibition abrogates myoblast fusion and differentiation ([@BIO033670C37]). Based on this observation, we next investigated whether p38 MAPK takes part in the S-phase peak and later G0/G1 arrest promoted by SGE in C2C12 cells. To achieve this, first C2C12 cells were cultured in growth medium (GM), and then this medium was changed to differentiation medium (DM) to induce differentiation. Cells were treated with synthetic SGE (10 nM) in the presence or absence of p38 MAPK inhibitor SB 203580 (10 µM) or vehicle alone for 12 h and 24 h. As illustrated in [Fig. 1](#BIO033670F1){ref-type="fig"}B, SGE-induced G0/G1 cell arrest was abrogated when p38 MAPK was previously inhibited, showing that SGE activates the p38 MAPK pathway to promote the onset of muscle differentiation.

It has been reported that 1α,25(OH)~2~D~3~ stimulates the PI3K-Akt pathway ([@BIO033670C12]) and other well-supported evidence has suggested that AKT signaling has an important role in myoblast differentiation ([@BIO033670C20]; [@BIO033670C15]; [@BIO033670C42]). It was reported that AKT overexpression enhances myoblast differentiation, whereas AKT inhibition, by expression of a dominant-negative AKT, blocks myotube formation. The suppression of myogenesis caused by PI3-kinase inhibition is rescued by the ectopic expression of a constitutively active AKT ([@BIO033670C41])*.* AKT participation in C2C12 differentiation by 1α,25(OH)~2~D~3~ was previously reported in C2C12 ([@BIO033670C9]). However, an experimental approach different from ours was used. In that report, cells were grown in DM medium for 48 h before 1α,25(OH)~2~D~3~ (1 nM) treatment, and thus a different pattern of AKT phosphorylation was observed. In view of p38 MAPK and AKT implication in muscle cells differentiation, we then studied whether SGE regulates p38 MAPK and AKT likewise regulates 1α,25(OH)~2~D~3~. To that end, time course experiments were performed during SGE (10 nM) or synthetic 1α,25(OH)~2~D~3~ (1 nM) treatment at the beginning of C2C12 differentiation (1--48 h). Proteins from whole cell lysates were subjected to SDS-PAGE and p38-MAPK, and AKT protein phosphorylation was analyzed by Western blot. The results presented in [Fig. 2](#BIO033670F2){ref-type="fig"} show that AKT phosphorylation increased rapidly at 1 h and then decreased significantly after SGE or 1α,25(OH)~2~D~3~ treatment (24--48 h), whereas p38 MAPK phosphorylation also increased at 1 h and remained elevated for 24 h to decrease later (48 h). Our study supports the hypothesis that the effects of SGE in AKT phosphorylation are similar to synthetic 1α,25(OH)~2~D~3~. Fig. 2.**SGE regulates AKT and p38 MAPK phosphorylation at the beginning of myogenesis.** C2C12 cells were cultured in GM. To begin the differentiation, this medium was withdrawn and then replaced by DM. Treatment was started by adding 10 nM of SGE or 1 nM of synthetic 1α,25(\|OH)~2~D~3~ (1,25D) in DM during different periods of time (1--48 h). Western blots were performed with anti p-AKT, total AKT, p-p38 MAPK, and p38α and tubulin antibodies. Tubulin was used as loading protein marker. Representative blots from three independent experiments (upper panel) and their quantification (lower panel) are shown. Protein bands quantification was done using ImageJ. Results were then represented in bar graphs as phosphorylated protein normalized with its corresponding total from treated conditions and referred to control (Fold) (lower panel). Significant differences between conditions at each time point were analyzed by Student's *t*-test, \*\**P*\<0.01.

Myoblast fusion is essential for the development of skeletal muscle myofibers. The formation of multinucleated muscle cells through cell-fusion is a conserved mechanism from fruit flies to humans. Cell-cell fusion of myoblasts give rise to the functional unit of muscle, the multinucleated myofiber ([@BIO033670C1]).

We have previously shown that SGE as synthetic 1α,25(OH)~2~D~3~ induces myoblasts fusion into myotubes (Gili el at., 2016)*.* Results from our laboratory have indicated that p38 MAPK activation by 1α,25(OH)~2~D~3~ is VDR-dependent in C2C12 myoblasts under a proliferative stage ([@BIO033670C10]). It was also shown that c-Src-dependent stimulation of MKK3 and 6 rapidly activates p38 MAPK, which in turn phosphorylates MAPK2 that subsequently promotes the phosphorylation of heat-shock protein 27 in C2C12 myoblasts. In agreement with our findings, p38 MAPK involvement in cell-cycle control of C2C12 cells stimulated with 1 nM of 1α,25(OH)~2~D~3~ has been previously demonstrated, providing key information of a 1α,25(OH)~2~D~3~ mechanism in myogenesis regulation ([@BIO033670C10]). Thus, our study demonstrates SGE's effect on signaling pathways involved in myogenesis.

Four isoforms of p38 MAPK have been described; Wang and collaborators have found that p38α, β and γ are required for C2C12 cell differentiation ([@BIO033670C44]). SB203580 specifically inhibits p38 isoforms α and β and has been successfully used to elucidate the role of these isoforms. Results obtained using this inhibitor have implicated p38α and β in skeletal muscle differentiation *in vitro* ([@BIO033670C26]). p38 MAPK signal enables myoblasts to exit the cell cycle at the beginning of differentiation ([@BIO033670C28]). Since p38α is a key signaling pathway involved in skeletal muscle differentiation and inhibition of p38α activity abrogates myoblast differentiation and fusion ([@BIO033670C37]), we assessed whether p38 MAPK, activated by SGE, takes part in the fusion of C2C12 cells to form myotubes during differentiation. To that end, C2C12 cells were induced to differentiate in DM and treated with SGE (10 nM) or synthetic 1α,25(OH)~2~D~3~ (1 nM) in the presence or absence of SB203580 (10 µM), or vehicle alone for 72 h. At the end of the treatment, cells were fixed and incubated with anti-β-actin antibody and DAPI, and then examined using a fluorescence microscope. Images were collected and the fusion index was calculated as described in the Materials and Methods. As illustrated by [Fig. 3](#BIO033670F3){ref-type="fig"}, myotubes were developed in cells exposed to DM for 72 h (control) and it was statistically and similarly increased by either SGE or 1α,25(OH)~2~D~3~. When cells were incubated with SB203580, cell fusion was blocked. Moreover, when SB203580 was used in combination with SGE (10 nM) or 1α,25(OH)~2~D~3~ (1 nM), the ability of both compounds to induce myotube formation was impaired ([Fig. 3](#BIO033670F3){ref-type="fig"}B). As reported by [@BIO033670C25], our studies confirm that p38α and β treated by 1α,25(OH)~2~D~3~ are implicated in the withdrawal of myoblasts from the cell cycle to promote differentiation. Furthermore, our results expand the knowledge of the SGE mechanism that triggers myoblast fusion through p38 MAPK. Fig. 3.**SB203580 and LY294002 inhibitors prevent** **myoblast** **differentiation induced by SGE or synthetic 1α,25(OH)~2~D~3~.** (A) Fluorescence photomicrographs show C2C12 cells undergoing differentiation for 72 h. Cells were treated with vehicle (Ctrl, control), 1 nM of 1α,25(OH)~2~D~3~ (1,25D), or 10 nM of SGE, or in presence of SB203580 (10 µM), or LY294002 (10 µM), as described in the text. (B) Fusion index was calculated and represented in bar graphs from three independent experiments. Significant differences between conditions were analyzed by one way ANOVA followed by Bonferroni Test. Different letters indicate statistical differences among groups for each condition (*P*\<0.05).

Since AKT activation induced by synthetic 1α,25(OH)~2~D~3~ in skeletal muscle differentiation was previously reported ([@BIO033670C9]), to study AKT participation in myotube fusion promoted by SGE, the inhibitor LY294002 was used. LY294002 (10 µM) has been shown to effectively block PI3K activation upstream of AKT in C2C12 cells by other authors ([@BIO033670C16]). As indicated in [Fig. 3](#BIO033670F3){ref-type="fig"}A and B, inhibition of AKT activity blocked myotube fusion induced by SGE as well as 1α,25(OH)~2~D~3~, showing that AKT signaling is also part of SGE mechanism to trigger C2C12 differentiation.

Until now, myogenic regulation is a theme of study. The precise molecular mechanism is being explored and many novel genes and factors are emerging as new candidates. In this regard, a number of transcription factors and muscle-specific genes have been confirmed as muscle determination factors ([@BIO033670C7]; [@BIO033670C45], [@BIO033670C46]). In this context, we next studied the pattern of *myoD1*, *myogenin* and *MCH2b* gene expression during the differentiation phase. C2C12 were cultured for 24 h in GM, which was then replaced with DM and SGE (10 nM), 1α,25(OH)~2~D~3~ (1 nM) or vehicle was added for 24--72 h. mRNA gene expression was then analyzed by qRT-PCR. As can be observed in [Fig. 4](#BIO033670F4){ref-type="fig"}A, *myoD1* mRNA control levels remained low throughout the period of analysis whereas in treated conditions, *myoD1* mRNA increased upon the addition of SGE or 1α,25(OH)~2~D~3~. SGE-induced mRNA synthesis was sustained during the period of analysis in contrast to synthetic 1α,25(OH)~2~D~3~ that only increased significantly at 24 h ([Fig. 4](#BIO033670F4){ref-type="fig"}A). The early differentiation marker *myogenin* also increased upon SGE or 1α,25(OH)~2~D~3~ treatment, however, *myogenin* mRNA induction by 1α,25(OH)~2~D~3~ started at 48 h in contrast to SGE ([Fig. 4](#BIO033670F4){ref-type="fig"}B). Finally, the late differentiation marker, *MHC2b*, also increased significantly by SGE or 1α,25(OH)~2~D~3~ at 72 h compared to control ([Fig. 4](#BIO033670F4){ref-type="fig"}C). Fig. 4.**Genes regulation by SGE or synthetic 1α,25(OH)~2~D~3~ during onset of differentiation.** C2C12 cells were treated with SGE (10 nM), 1α,25(OH)~2~D~3~ (1,25D, 1 nM), or vehicle alone (ctrl) in DM in time course experiments (24--72 h). Total RNA was extracted and reverse transcribed and data analysis was performed for each gene expression by qRT-PCR. Bar graphs show quantitative results from three experiments performed in duplicate and expressed as a ratio between mRNA of each gene (A) *myoD1*, (B) *myogenin*, (C) *MHC2b* in DM under control conditions (ctrl) or treated (1,25D or SGE) previously normalized to GAPDH mRNA levels and to GM (time 0). The results were then represented in bar graphs. Significant differences between control and treated (SGE or 1,25D) conditions at each time point were analyzed by Student\'s *t*-test. ns: not significant. \**P*\<0.05 and \*\**P*\<0.01.

In conclusion, our results indicate that SGE regulates the cell cycle and promotes myotube fusion through p38 MAPK and AKT regulation in skeletal muscle C2C12 cells. Moreover, both vitamin D metabolites, SGE and synthetic 1α,25(OH)~2~D~3~, modulate gene expression during myogenesis.

MATERIALS AND METHODS {#s3}
=====================

Chemicals and reagents {#s3a}
----------------------

We obtained 1α,25(OH)~2~D~3~ from Cerbios AG, Lugano, Switzerland (<http://www.cerbios.ch>) and an extract of dry leaves of the plant *S.* *glaucophyllum*, containing 50 µg g^−1^ analytically determined 1α,25(OH)~2~D~3~, was kindly provided by Herbonis AG (Augst, Switzerland). Dulbecco\'s modified Eagle\'s medium (DMEM) low glucose, with l-glutamine and HEPES, without phenol red, Immobilon P (PVDF) membranes, LY294002 and SB 203580 were from Sigma-Aldrich. Sterile fetal bovine serum (FBS) and horse serum (HS) were purchased from Natocor (Córdoba, Argentina). The antibodies used were: anti-p-p38 MAPK (4511), p-AKT (9271), AKT (4685) from Cell Signaling Technology; Goat anti-Rabbit, IgG-HRP (sc-2004) and anti-β-actin (sc-47778) antibodies from Santa Cruz Biotechnology. DAPI, β-tubulin antibody, Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Cyanine3 were from Thermo Fisher Scientific. PCR primers, Superscript III reverse transcriptase (Invitrogen), Sybr green PCR master mix (Applied Biosystems) were also from Thermo Fisher Scientific. High Pure RNA Isolation Kit was from Roche (F. Hoffmann-La Roche Ltd., Madison, USA).

Cell culture and treatment {#s3b}
--------------------------

We used the murine skeletal muscle cell line C2C12 to study myogenesis ([@BIO033670C19]). Cells were cultured with DMEM supplemented with 10% heat-inactivated (30 min, 56°C) FBS, 1% nystatine, and 1% streptomycin, GM at 37°C under a humidified atmosphere of 5% CO~2~ in air. C2C12 myoblasts cultured in these conditions resemble the activated satellite cells ([@BIO033670C48]). Myoblast differentiation was promoted as was previously reported ([@BIO033670C19]). Briefly, (with C2C12 cells at 70--80% of confluence) GM was replaced with DMEM without phenol red, supplemented with 2% HS (DM). C2C12 cells were incubated in DM with 1α,25(OH)~2~D~3~ (1 nM) or SGE (10 nM) dissolved in less than 0.01% ethanol as vehicle during the experimental period.

Cell lysates and protein content determination {#s3c}
----------------------------------------------

C2C12 cells were scraped in 75 µl of lysis buffer and lysates were collected by aspiration and centrifuged at 14,000 ***g*** for 15 min ([@BIO033670C19]). Proteins from supernatant were quantified using the Bradford procedure as before ([@BIO033670C19]; [@BIO033670C6]).

Western blot analysis {#s3d}
---------------------

Proteins were separated on SDS-PAGE (10% gels) and electro transferred to PVDF membranes. Membranes were then blocked and subjected to immunoblotting ([@BIO033670C19]). Incubation with primary antibodies, (1:1000) in 0.1% TBST containing 2.5% dry milk, was performed overnight at 4°C. After washing three times with 0.1% TBST, membranes were incubated with secondary antibodies conjugated with peroxidase (1:5000) in TBST buffer as primary antibodies, for 1 h at room temperature. Blot signals were visualized using an enhanced chemiluminescence technique (ECL) according to the manufacturer\'s instructions (Amersham ECL Western Blotting Detection Kit, GE Healthcare). Images were scanned and quantified using ImageJ software.

Fluorescence microscopy {#s3e}
-----------------------

Cells were fixed with formaldehyde for 15 min. Fixed cells were then incubated with anti-β-actin (1:50) overnight at 4°C and then with Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Cyanine3 for 1 h and then with DAPI (1:1000) of a stock solution of 5 mg ml^−1^ for 30 min at room temperature, in darkness. Samples were then washed three times with phosphate-buffered saline (PBS), mounted and examined using NIKON Eclipse Ti-S fluorescence microscope equipped with standard filter sets ([@BIO033670C19]). Images were collected using a digital camera.

Fusion index determination {#s3f}
--------------------------

Images collected from Fluorescence microscopy were merged with Fiji software (ImageJ) and the fusion index was calculated as in our previous work ([@BIO033670C19]). Briefly, the fusion index (number of nuclei in myotubes/total number of nuclei) was calculated by counting nuclei in ten random fields from three culture dishes (five fields in each dish).

Cell cycle analysis by flow cytometry {#s3g}
-------------------------------------

C2C12 cells were collected by trypsinization, washed with PBS twice and then fixed in 70% of ethanol. Fixed cells were washed in PBS and re-suspended with 500 µl of RNase-propidium iodide mix (BD Biosciences) for 30 min. The fluorescence of DNA was measured using a flow cytometer (BD FACSCalibur) and the cell distribution in different phases of the cellular cycle was analyzed by computer software (CELLQuest PRO, Becton Dickinson, San Jose, USA).

RNA Isolation and quantitative RT-PCR {#s3h}
-------------------------------------

Total RNA for quantitative RT-PCR (qRT-PCR) analysis was isolated with the High Pure RNA Isolation Kit (Roche) following the procedure provided by manufacturer. Then 1 µg of RNA was reverse transcribed using the Superscript III Reverse transcriptase and qRT-PCR reactions were performed on the resulting cDNA in a 7500 Fast Real Time PCR system (Applied Biosystems). Specific primers were used to detect *myoD1*, *myogenin* and *MHC2b* mRNA levels. *Gapdh* mRNA was used to normalize gene expression. Data of relative fold change was obtained by the comparative CT method. Oligonucleotides used for amplification were: murine *myoD1*: forward 5′-CAACGCCATCCGCTACATCG-3′ and reverse 5′-GTCCAGGTGCGTAGAAGGCA-3′; murine *myogenin*: forward 5′-TGCCGTGGGCATGTAAGGT-3′ and reverse 5′-TGCGCAGGATCTCCACTTTAG-3′ and murine *MHC2b*: forward 5′-CAATCAGGAACCTTCGGAACAC-3′ reverse 5′-CAATCAGGAACCTTCGGAACAC-3′ and murine *Gapdh*, forward 5′-GAAGGTGAAGGTCGGAGTC-3′ and reverse 5′-GAAGATGGTGATGGGATTTC-3′.

Statistical analysis {#s3i}
--------------------

Data are shown as mean±s.d. Cell cycle statistical analysis was performed by one way ANOVA, followed by Tukey test. Index fusion was analyzed by one way ANOVA, followed by Bonferroni test. Different superscript letters indicate significant differences at *P*\<0.05. Data from DNA quantification in [Fig. 1](#BIO033670F1){ref-type="fig"}A, time-response studies obtained by qRT-PCR or Western blot were analyzed by the two-tailed *t*-test. \*\**P*\< 0.01 and \**P*\< 0.05 were considered statistically significant.
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